Motley Fool
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
📈
AI Sentiment
Highly Positive
9/10
- Home
- MLYS
as of 12-26-2025 3:59pm EST
$37.07
$0.36
-0.96%
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 3.1B | IPO Year: | 2023 |
| Target Price: | $47.33 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $47.65 | Next Earning Date: | 02-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MLYS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 71.19%
71.19%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
Karydas Daphne
Sell
Director
MLYS Nov 13, 2025
Avg Cost/Share
$46.08
Shares
15,000
Total Value
$689,797.08
Owned After
0
Gold Alexander M
Sell
Director
MLYS Nov 13, 2025
Avg Cost/Share
$46.50
Shares
12,742
Total Value
$592,503.00
Owned After
0
SEC Form 4
Gold Alexander M
Sell
Director
MLYS Nov 12, 2025
Avg Cost/Share
$46.89
Shares
6,933
Total Value
$323,885.67
Owned After
0
Congleton Jon
Sell
Chief Executive Officer
MLYS Nov 11, 2025
Avg Cost/Share
$44.23
Shares
200,000
Total Value
$9,088,498.87
Owned After
631,305
Levy Adam Scott
Sell
CFO and Secretary
MLYS Nov 11, 2025
Avg Cost/Share
$43.56
Shares
119,524
Total Value
$5,363,715.88
Owned After
103,612
Gold Alexander M
Sell
Director
MLYS Nov 11, 2025
Avg Cost/Share
$44.76
Shares
15,000
Total Value
$659,706.00
Owned After
0
Rodman David Malcom
Sell
Chief Medical Officer
MLYS Oct 15, 2025
Avg Cost/Share
$43.01
Shares
10,369
Total Value
$445,982.10
Owned After
71,155
SEC Form 4
Congleton Jon
Sell
Chief Executive Officer
MLYS Oct 13, 2025
Avg Cost/Share
$42.83
Shares
15,100
Total Value
$644,326.87
Owned After
631,305
Levy Adam Scott
Sell
CFO and Secretary
MLYS Oct 13, 2025
Avg Cost/Share
$42.08
Shares
10,758
Total Value
$451,983.56
Owned After
103,612
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Karydas Daphne | MLYS | Director | Nov 13, 2025 | Sell | $46.08 | 15,000 | $689,797.08 | 0 | |
| Gold Alexander M | MLYS | Director | Nov 13, 2025 | Sell | $46.50 | 12,742 | $592,503.00 | 0 | |
| Gold Alexander M | MLYS | Director | Nov 12, 2025 | Sell | $46.89 | 6,933 | $323,885.67 | 0 | |
| Congleton Jon | MLYS | Chief Executive Officer | Nov 11, 2025 | Sell | $44.23 | 200,000 | $9,088,498.87 | 631,305 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Nov 11, 2025 | Sell | $43.56 | 119,524 | $5,363,715.88 | 103,612 | |
| Gold Alexander M | MLYS | Director | Nov 11, 2025 | Sell | $44.76 | 15,000 | $659,706.00 | 0 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Oct 15, 2025 | Sell | $43.01 | 10,369 | $445,982.10 | 71,155 | |
| Congleton Jon | MLYS | Chief Executive Officer | Oct 13, 2025 | Sell | $42.83 | 15,100 | $644,326.87 | 631,305 | |
| Levy Adam Scott | MLYS | CFO and Secretary | Oct 13, 2025 | Sell | $42.08 | 10,758 | $451,983.56 | 103,612 |
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
Compare MLYS vs Leading Stocks
See how MLYS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.